Form 4 for CV CapsoVision, Inc
Accepted 2025-08-22 00:00:00 ET · period of report 2025-08-18 · accession 0001378325-25-000014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-08-22 | 2025-08-18 | CV | Petersen Rebecca Ann | Dir of Clinical Affairs | M - OptEx | $0.37 | +24.8K | 24.8K | New | +$9,189 |
| DM | 2025-08-22 | 2025-08-18 | CV | Petersen Rebecca Ann | Dir of Clinical Affairs | M - OptEx | $0.00 | -24.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-18 | M | A | 24,834 | $0.37 | 24,834 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2025-08-18 | M | D | 17,327 | $0.00 | 3,694 | D | $0.37 · — to 2032-03-22 | 17,327 Common Stock | (F3) There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. (F1) These options were previously reported at exercise price of $0.11 per share. The exercise price reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. (F4) The option was granted on March 23, 2022 and is partially vested and exercisable as of the transaction date. |
| 3 | Derivative | Stock Option (right to buy) | 2025-08-18 | M | D | 7,507 | $0.00 | 0 | D | $0.37 · — to 2031-10-31 | 7,507 Common Stock | (F3) There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. (F1) These options were previously reported at exercise price of $0.11 per share. The exercise price reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering. (F2) The option was granted on October 28, 2021 and is fully vested and exercisable as of the transaction date. |